Posts

Posted on

InPlay Oil Announces Participation in Noble Capital Markets Virtual Road Show Series

CALGARY, Alberta, Nov. 19, 2020 (GLOBE NEWSWIRE) — InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) a junior oil and gas exploration and production company with operations in Alberta focused on light oil production, today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for November 23, 2020.

The virtual road show will feature a corporate presentation from InPlay Oil CEO, Doug Bartole, followed by a Q & A session proctored by Noble Senior Research Analyst Michael Heim, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for November 23, 2020, at 1 PM EDT. Registration is free, but limited to 100. Register Here.


About InPlay Oil:

InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX under the symbol IPOOF.


About Noble Capital Markets

Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: [email protected]


About


Channelchek

Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. www.channelchek.com email: [email protected]

For further information please contact:

Doug Bartole
President and Chief Executive Officer
InPlay Oil Corp.
Telephone: (587) 955-0632		 Darren Dittmer
Chief Financial Officer
InPlay Oil Corp.
Telephone: (587) 955-0634



Posted on

BlackRock Enhanced Government Fund, Inc. Completes Annual Repurchase Offer

BlackRock Enhanced Government Fund, Inc. Completes Annual Repurchase Offer

NEW YORK–(BUSINESS WIRE)–
BlackRock Enhanced Government Fund, Inc. (the “Fund”) (NYSE:EGF, CUSIP: 09255K108) today announced the completion of its annual offer to repurchase a portion of its outstanding shares of common stock from its stockholders (the “Repurchase Offer”).

Under the terms of the Repurchase Offer, the Fund offered to repurchase up to 10% of its issued and outstanding shares of common stock (the “Shares”) for cash at a price equal to the Fund’s net asset value per Share calculated as of the close of business of the New York Stock Exchange on November 19, 2020 (subject to the repurchase fee of 2% of the net asset value per Share, which was deducted from the repurchase price (the “Repurchase Fee”)).

As previously announced on November 18, 2020, the expiration date of the Repurchase Offer, Computershare Trust Company, N.A., the Fund’s depositary agent, indicated that 1,202,530 Shares (approximately 25% of the Fund’s Shares outstanding as of November 18, 2020) were validly submitted for tender and not withdrawn. Since more than 10% of the Fund’s outstanding Shares were validly submitted for tender, the Fund repurchased validly tendered Shares on a pro rata basis. However, the Fund accepted all Shares validly submitted for tender by stockholders who owned, beneficially or of record, an aggregate of not more than 99 Shares and who validly tendered all of their Shares, before pro rating Shares validly tendered by other stockholders. Consequently, approximately 39% of Shares validly submitted for tender were accepted for repurchase.

On November 19, 2020, and subject to pro ration as applicable, validly tendered Shares were repurchased by the Fund at $13.13 per Share, the Fund’s net asset value per Share determined as of 4:00 p.m. EST, Thursday, November 19, 2020 (subject to the Repurchase Fee). Shares validly tendered and accepted will not be entitled to receive any Fund dividend or distribution with a record date on or after November 24, 2020.

The Fund is a diversified, closed-end management investment company. The Fund’s investment objective is to provide stockholders with current income and gains.

None of the Fund, its investment adviser or its Board of Directors made any recommendation to any stockholder as to whether to tender or refrain from tendering Shares in the Repurchase Offer.

For client-specific information regarding the Repurchase Offer, please contact your broker or financial advisor, or in the case of registered stockholders, Computershare Trust Company, N.A., which is acting as the depositary agent in connection with the Repurchase Offer.

About BlackRock

BlackRock helps investors build better financial futures. As a fiduciary to investors and a leading provider of financial technology, our clients turn to us for the solutions they need when planning for their most important goals. As of September 30, 2020, the firm managed approximately $7.81 trillion in assets on behalf of investors worldwide. For additional information on BlackRock, please visit www.blackrock.com | Twitter: @blackrock | Blog: www.blackrockblog.com | LinkedIn: www.linkedin.com/company/blackrock

Availability of Fund Updates

BlackRock will update performance and certain other data for the BlackRock closed-end funds (the “Funds”) on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock’s website in this release.

Forward-Looking Statements

This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund’s net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.

Annual and Semi-Annual Reports and other regulatory filings of the Fund with the Securities and Exchange Commission (“SEC”) are accessible on the SEC’s website at www.sec.govand on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Fund. The information contained on BlackRock’s website is not a part of this press release.

BlackRock Closed-End Funds

1-800-882-0052

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Sotera Health Announces Pricing of Initial Public Offering

CLEVELAND, Nov. 19, 2020 (GLOBE NEWSWIRE) — Sotera Health Company today announced the pricing of its initial public offering (“IPO”) of 46,600,000 shares of its common stock at a price to the public of $23.00 per share. The gross proceeds of the offering are expected to be approximately $1.1 billion, before deducting underwriting discounts and commissions and offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an additional 6,990,000 shares.

The shares are expected to begin trading on the Nasdaq Global Select Market on November 20, 2020, under the symbol “SHC.” The offering is expected to close on November 24, 2020, subject to customary closing conditions.

J.P. Morgan, Credit Suisse, Goldman Sachs & Co. LLC and Jefferies are acting as joint lead book-running managers and as representatives of the underwriters for the offering. Barclays, Citigroup and RBC Capital Markets are acting as joint book-running managers for the offering. BNP PARIBAS, KeyBanc Capital Markets, Citizens Capital Markets, ING, Academy Securities, Loop Capital Markets, Penserra Securities LLC, Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from: J.P. Morgan Securities, LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at [email protected]; Credit Suisse Securities (USA), LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone 1-866- 471-2526 or by email at [email protected]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone 1-877-821-7388 or by email at [email protected].

A registration statement relating to these securities was declared effective as of November 19, 2020 by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-looking Statement:

Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-1 filed with the SEC, including under the headings of “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law.

About
Sotera
Health:

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

CONTACTS:

Sally J. Curley, IRC Jenny Kobin
Curley Global IR, LLC IR Advisory Solutions
[email protected]  [email protected] 
   
Kristin Gibbs  
Chief Marketing Officer, Sotera Health  
[email protected]   

Source: Sotera Health Company



Posted on

Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering

Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering

BEDFORD, Mass.–(BUSINESS WIRE)–
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $39.00 per share. The gross proceeds from this offering are expected to be $97.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke. The offering is expected to close on or about November 24, 2020, subject to the satisfaction of customary closing conditions. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by Stoke.

J.P. Morgan Securities LLC, Cowen and Company, LLC, and Credit Suisse Securities (USA) LLC are acting as joint book-running managers in the offering. Canaccord Genuity LLC and Cantor Fitzgerald & Co. are acting as passive bookrunners in the offering.

Stoke intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to fund research, clinical and process development and manufacturing of its product candidates, including late stage development of STK-001, clinical development of its next target for the treatment of Autosomal Dominant Optic Atrophy, developing additional product candidates, working capital, capital expenditures and other general corporate purposes.

The shares are being offered by Stoke pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, and when available, the final prospectus supplement, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (866) 803-9204, or by emailing [email protected]; from Cowen and Company, LLC c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (833) 297-2926, or by emailing [email protected]; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at [email protected]. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Stoke, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company makes regarding its expectation of market conditions and the satisfaction of customary closing conditions related to the offering, its ability to complete the offering and expected use of proceeds, Stoke’s plan to develop its precision medicine platform, anticipated preclinical and clinical development activities, potential benefits of Stoke’s product candidates and potential market opportunities for Stoke’s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Stoke believes that the expectations reflected in such forward-looking statements are reasonable, Stoke cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, market conditions, the satisfaction of customary closing conditions related to the proposed offering, as well as other risks and uncertainties described under the heading “Risk Factors” in documents Stoke files from time to time with the SEC. These forward-looking statements speak only as of the date hereof and Stoke specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

Stoke Media & Investor Contact:

Dawn Kalmar

Vice President, Head of Corporate Affairs

[email protected]

781-303-8302

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Other Health Research Banking General Health Professional Services Genetics Other Professional Services Science Biotechnology Finance Other Science Health

MEDIA:

Logo
Logo
Posted on

CAAP Announces Its Subsidiary ICASGA Executes Amendment to Allow for Friendly Termination of Its Natal Airport Concession

CAAP Announces Its Subsidiary ICASGA Executes Amendment to Allow for Friendly Termination of Its Natal Airport Concession

LUXEMBOURG–(BUSINESS WIRE)–Corporación América Airports S.A. (NYSE: CAAP), (“CAAP” or the “Company”) the largest private sector airport concession operator in the world by number of airports, announced today that its subsidiary Inframérica Concessionária do Aeroporto de São Gonçalo do Amarante S.A. (“ICASGA”) executed an irrevocable amendment for the termination of the concession agreement of the International Airport of São Gonçalo do Amarante (“Natal Airport”). Upon transfer to a new operator, an indemnification payment will be made to ICASGA, which will be determined by authorities, primarily based on non-amortized capital expenditure investments. The amendment and termination is limited to the Natal Airport concession.

The process to terminate the concession agreement of the Natal Airport was initiated on March 5, before the pandemic broke in LatAm, with the goal of transferring the concession of this airport to a different operator. The Ministry of Infrastructure in Brazil has already started the feasibility studies for the new concession, although the new auction has not yet been scheduled. In the interim, ICASGA will maintain all airport operations, with the same safety and service quality, as well as commercial and employment contracts, and will continue to work with the Government of Rio Grande do Norte to attract new flights and destinations to the region.

This process is carried out strictly in compliance with the existing Brazilian legal and regulatory framework.

Mr. Martín Eurnekian, CEO of Corporación America Airports, noted: “The so-called friendly termination of the concession of Natal Airport is the best course of action for all stakeholders, as the operation of this airport has become financially challenging given the current concession framework and the impact on passenger traffic from adverse economic conditions in Brazil. In the meantime, we will continue to fulfill all our contractual obligations, serving passengers and partners, as well as executing all the contracts in force with employees and airlines, and we remain committed to assist when a new company takes over the management and operations.”

Several factors drove the Company’s decision to seek return of this concession, including the negative impact on passenger traffic as a result of the 2016 and 2017 economic crisis. In addition, passenger tariffs lag those of all other privatized airports in the country under the same tariff scheme, and air navigation tariffs charged in other airports are approximately 300% higher than in Natal Airport.

Natal Airport was the first airport in Brazil transferred to the private sector, in 2011, and the first greenfield federal airport built by the private sector. It began operations in May 2014, providing the local population and visitors a new, modern and comfortable facility. As of December 2019, the total amount of investments in Natal Airport was approximately R$ 700 million in nominal terms.

About Corporación América Airports

Corporación América Airports acquires, develops and operates airport concessions. Currently, the Company operates 52 airports in 7 countries across Latin America and Europe (Argentina, Brazil, Uruguay, Peru, Ecuador, Armenia and Italy). In 2019, Corporación América Airports served 84.2 million passengers. The Company is listed on the New York Stock Exchange where it trades under the ticker “CAAP”. For more information, visit http://investors.corporacionamericaairports.com.

Investor Relations Contact
Gimena Albanesi

Email: [email protected]

Phone: +5411 4852-6411

KEYWORDS: Europe Luxembourg United States North America New York

INDUSTRY KEYWORDS: Air Destinations Transport Travel

MEDIA:

Logo
Logo
Posted on

Aurora Spine Corporation Announces Financial Results for Third Quarter

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES


Gross margin improves t


o


48


%


,


revealing


company on track with FY20 strategy


of selling more proprietary


products

CARLSBAD, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (US: AROSF), a company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies, today announced the financial results for the third quarter ended September 30, 2020. All figures are in U.S. dollars.

Financial
and
Business
Highlights

  • Reported revenues of $2.4 million in Q3 2020, compared to $1.6M in Q2 and $2.3M in Q1. Compared to Q3 2019, it represents a decrease of 6%.
  • Sequential improvement of gross margin to 48.0% in Q3, up from 40.9% in Q2, and 34.6% in Q1, due to sales mix that included more proprietary products.
  • EBITDAC during Q3 2020 was approximately $132k before including $345k of Personal Payroll Protection funds brought into income during the period. EBITDAC is a non-GAAP, non IFRS measure defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation and other income.
  • Strong cash retention, company ended Q3 with $2.1 million in cash.
  • Aurora Spine was issued United States Patent No: 10,779,954 entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for The World’s First DEXA Technology™ Patient-Matched Implant Technology.

Management Commentary

Mr. Trent Northcutt, President and C.E.O. of Aurora Spine, stated, “Third quarter financial results rebounded nicely as elective surgeries in the U.S. resumed. The quarter also demonstrated that our strategy implemented earlier in the year, converting third-party products into proprietary products, is well underway as gross profit margins improved to 48%. During the third quarter, proprietary products were 63% of revenue and we are on track to convert nearly all revenues to proprietary products, with the exception of lumbar screws, by the end of the year.”

Mr. Northcutt continued, “During the quarter we received notice from the USPTO regarding the issuance of a patent entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for the world’s first DEXA Technology™ Patient-Matched Implant Technology. This patent will be utilized to create implants that match the patient’s specific bone density based on a DEXA Scan/T-score allowing for the best bone fusion treatment and most favorable outcome based on that patient’s bone density. We believe that in the coming years this patent will add tremendous value to Aurora and we have begun to lay the groundwork, including clinical trial work, to develop new cervical interbody cages based on the DEXA technology and may consider out-licensing the technology to other companies.”

Mr. Northcutt concluded, “I continue to be proud of the Aurora team during these challenging times and thank them for their hard work and dedication. Throughout the pandemic our team has been able to continue progressing Aurora’s new product strategy in trialing the SOLOTM and SiLOTM product launches. We also continue to be prudent in preserving the capital that was raised earlier in the year and this puts the company in a solid financial position to launch more proprietary products, which we plan to do throughout the remainder of the year and during 2021. Thankfully, our strategy is in motion and the company is positioned for renewed growth into 2021 and beyond.”

Mr. Chad Clouse, Chief Financial Officer of Aurora Spine, added, “The third quarter was a financially strong and profitable one for Aurora. This was accomplished by improved gross profit margin, which has continued to improve since the company implemented a shift into producing more proprietary products. Expense controls were also a contributing factor to a profitable quarter as the company incurred lower employee costs and marketing expenses. We expect operating expenses to increase to more normalized levels in the coming quarters to support the company’s launch of several new products and initiatives, which should also lead to continued revenue and gross profit margin improvements.”

Financial Results

Total revenues for the third quarter of 2020 were $2.37 million compared to $2.53 million for the third quarter of 2019, a decrease of 6.3%, but a sequential increase of 50.0% from second quarter 2020 of $1.58 million, as elective surgeries resumed from the Covid-19 shutdown in the first half of the second quarter. Revenues continued to increase throughout the third quarter 2020, with revenue in August and September being slightly higher than the same periods of 2019.

Gross margins on total revenues were 48.0% for the third quarter of 2020, compared to 40.0% during the third quarter of 2019. The improvement in gross margins is attributable to the company’s strategy of converting third party product sales to more proprietary, Aurora Spine products.

Total operating expenses were $1.147 million for the third quarter of 2020 compared to $1.43 million for the third quarter of 2019. The lower operating expenses were a result of a decrease in expenses due to the Covid-19 crisis, particularly in the area of employee costs. Marketing expenses also decreased due to the cancelation of tradeshows and less travel expenses due to travel restrictions. The company continues to maintain cost controls to preserve its capital for growth initiatives.

EBITDAC (a non-GAAP figure non IFRS measure defined as Earnings before Interest, Tax, Depreciation, Amortization and Stock based compensation) was $0.48 million for the third quarter of 2020, compared to $(0.12) million in the third quarter of 2019.

Net income was $0.34 million for the third quarter of 2020, compared to a loss of $(0.42) million in the third quarter of 2019. Basic and diluted net income per share was $0.01 per share in the third quarter of 2020 and $(0.01) per share for the third quarter of 2019.

Full financial statements can be found on SEDAR at (www.sedar.com).

SELECTED BALANCE SHEET INFORMATION

The following table summarizes selected key financial data.

As at September 30, 2020
$		 December 31, 2019
$		 December 31, 2018
$
Cash 2,085,552 444,741 856,504
Trade receivables 1,585,613 2,443,096 1,584,269
Prepaid expenses and deposits 179,959 262,217 219,301
Inventory 1,721,999 1,529,474 2,562,957
Current assets 5,573,123 4,679,528 5,223,031
Intangible assets 827,954 838,915 853,529
Property and equipment 1,143,618 1,155,249 766,602
Total assets 7,544,695 6,673,692 6,843,162
Current liabilities 1,946,025 2,523,223 1,868,960
Long-term liabilities 2,313,005 2,382,444 2,016,000
Share capital 21,850,680 20,669,713 20,661,153

SELECTED QUARTERLY INFORMATION

The Company’s functional currency is the US dollar (USD). The functional currency of the Company’s US subsidiary Aurora is USD.

Operating results for each quarter for the last two fiscal years are presented in the table below.

Quarters ended September 30, 2020

$ 		June 30, 2020
$		 March 31, 2020
$		 December 31, 2019
$		 September 30, 2019

$ 		June 30, 2019
$		 March 31, 2019
$		 December 31, 2018
$
Revenue 2,368,692   1,580,450   2,259,251   2,632,649   2,530,602   3,260,247   2,729,221   2,500,976  
Cost of goods sold (1,230,824 ) (934,058 ) (1,478,037 ) (2,550,418 ) (1,518,986 ) (1,971,382 ) (1,564,504 ) (1,266,038 )
Gross profit 1,137,868   646,392   781,214   82,231   1,011,616   1,288,865   1,164,717   1,234,938  
Operating expenses 1,146,672** 831,239** 1,341,757   669,399* 1,429,015   1,332,970   1,370,318* 1,324,231*
EBITDAC*** 477,060   170,549   (294,721 ) (837,587 ) (116,189 ) 259,250   86,433   157,823  
Net income (loss) 336,163   34,475   (560,543 ) (587,168 ) (417,399 ) (44,105 ) (205,601 ) (89,293 )
Basic and diluted income (loss) per share**** 0.01   0.00   (0.01 ) (0.03 ) (0.01 ) (0.00 ) (0.00 ) (0.00 )

* Adjusted by gains and (losses) on sale of equipment.
** Excludes gain and (losses) from Other income (expense) of $219,322 in June 30, 2020 and $344,967 in September 2020. These are anticipated to be non-recurring.
*** EBITDAC is a non GAAP, non IFRS measure defined as Earnings before Interest, Tax, Depreciation, Amortization and Stock based compensation. This amount includes Gains (losses) on sale of property and equipment and Other income (expense).
**** Outstanding options and warrants have not been included in the calculation of the diluted loss per share as they would have the effect of being anti-dilutive.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward
–
looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
[email protected]



Posted on

Lilis Energy Announces Confirmation of Modified Debtors’ Liquidating Chapter 11 Plan

FORT WORTH, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) — Lilis Energy, Inc. (OTC: LLEXQ) (the “Company”), an exploration and development company operating in the Permian Basin of West Texas and Southeastern New Mexico, today announced that the United States Bankruptcy Court for the Southern District of Texas, Houston Division (the “Bankruptcy Court”) entered an order on November 17, 2020, among other things, confirming the Modified Debtors’ First Amended Joint Liquidating Chapter 11 Plan (the “Plan”) which received the overwhelming support of all creditors.

The Company expects that the effective date of the Plan ( the “Effective Date”) will be on or around December 1, 2020, assuming that all conditions precedent to the Plan’s effectiveness are satisfied or waived on or prior to such date, including the closing of the sale of substantially all of the assets of the Company and its subsidiaries pursuant to a previously disclosed Bankruptcy Court-approved purchase and sale agreement (the “Sale”). All proceeds from the Sale not distributed on the Effective Date pursuant to the Plan, and any miscellaneous assets not sold pursuant to the purchase and sale agreement or otherwise provided for in the Plan will be contributed to a liquidation trust pursuant to the Plan.

Under the Plan, the Company’s notes, instruments, certificates, credit agreements, indentures and other documents evidencing creditor claims or equity interests, including all outstanding shares of common and preferred stock of the Company, will be cancelled as of the Effective Date. Each of the Company and its subsidiaries will be dissolved and cease to exist on the Effective Date. The Plan provides for, among other things, the distribution of the proceeds from the Sale, a global settlement between and among the Company and its key economic stakeholders, and $786,750 of cash to fund recoveries for general unsecured creditors.

Information regarding the Chapter 11 process is available for free on the website maintained by Stretto, located at https://cases.stretto.com/LilisEnergy or by calling (855) 364-4639 (Toll-Free) or (949) 266-6357 (Local).

Vinson & Elkins LLP is serving as legal advisor to the Company, Barclays Capital is serving as investment banker for the Company, and Opportune LLP is serving as restructuring advisor to the Company.

About Lilis Energy, Inc.

Lilis Energy, Inc. is a Fort Worth based independent oil and gas exploration and production company that operates in the Permian’s Delaware Basin, considered amongst the leading resource plays in North America.

Forward-Looking Statements:

This news release contains “forward-looking statements” within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are not statements of historical facts and often contain words such as “may,” “will,” “expect,” “believe,” “anticipate,” “plan,” “estimate,” “seek,” “could,” “should,” “intend,” “potential,” or words of similar meaning. Forward-looking statements are based on management’s current expectations, beliefs, assumptions and estimates regarding the Company satisfying or obtaining waivers of the conditions precedent to the effectiveness of the Plan, including conditions precedent to close the sale of substantially all of the assets of the Company and its subsidiaries and other factors. The satisfaction or obtaining waivers of these conditions precedent to effectiveness of the Plan and the closing of the sale of substantially all of the assets of Debtors are subject to significant risks, uncertainties, and assumptions that are difficult to predict and could cause actual results or timing to differ materially and adversely from those expressed or implied in the forward-looking statements Additional factors, events, or uncertainties that may emerge from time to time, or those that the Company currently deems to be immaterial, could cause its actual results to differ, and it is not possible for the Company to predict all of them. The Company makes forward-looking statements based on currently available information, and it assumes no obligation to, and expressly disclaim any obligation to, update or revise publicly any forward-looking statements made in this report, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Christa Garrett
SVP General Counsel
817-720-9585

Source: Lilis Energy, Inc.



Posted on

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of CXO, CEIX, PNM, and EIDX Mergers

WILMINGTON, Del., Nov. 19, 2020 (GLOBE NEWSWIRE) —

Rigrodsky & Long, P.A. announces that it is investigating:

Concho Resources Inc. (NYSE:

CXO

) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips. Under the terms of the agreement Concho Resources’ shareholders will receive 1.46 shares of ConocoPhillips’ common stock per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-concho-resources-inc.

CONSOL Energy Inc. (NYSE:

CEIX

) regarding possible breaches of fiduciary duties and other violations of law related to CONSOL Energy’s agreement acquire all of the publicly held common units of CONSOL Coal Resources LP in an all-stock transaction valued at approximately $34.4 million. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-consol-energy-inc.

PNM Resources, Inc. (NYSE:

PNM

) regarding possible breaches of fiduciary duties and other violations of law related to PNM’s agreement to be acquired by Avangrid, Inc. Under the terms of the agreement PNM’s shareholders will receive $50.30 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-pnm-resources-inc.

Eidos Therapeutics, Inc. (NASDAQ GS:

EIDX

) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma, Inc. Under the terms of the agreement, Eidos’ shareholders will receive 1.85 shares of BridgeBio common stock or $73.26 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-eidos-therapeutics-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Posted on

Medical Properties Trust Announces Pricing of $1,300,000,000 3.500% Senior Notes Due 2031

Medical Properties Trust Announces Pricing of $1,300,000,000 3.500% Senior Notes Due 2031

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
Medical Properties Trust, Inc. (the “Company” or “MPT”) (NYSE: MPW) today announced the pricing of the previously announced public offering of notes to be issued by its operating partnership, MPT Operating Partnership, L.P. (the “Operating Partnership”), and MPT Finance Corporation, a wholly-owned subsidiary of the Operating Partnership (together with the Operating Partnership, the “Issuers”). The notes will mature on March 15, 2031 and priced with a coupon of 3.500%. Interest on the notes will be payable semi-annually in arrears commencing on March 15, 2021. The notes will be senior unsecured obligations of the Issuers, guaranteed by the Company. The offering is expected to close on December 4, 2020, subject to customary closing conditions.

The Issuers intend to use (i) approximately $833.0 million of the net proceeds from the offering to fund the redemption of all of their $300.0 million aggregate principal amount of 5.500% Senior Notes due 2024 and $500.0 million aggregate principal amount of 6.375% Senior Notes due 2024, including accrued and unpaid interest thereon, required make-whole premiums, and related fees and expenses, and (ii) the remainder of the net proceeds from the offering for general corporate purposes, which may include repaying amounts outstanding from time-to-time under the revolving credit facility, working capital and capital expenditures, and potential future acquisitions.

Goldman Sachs & Co. LLC, Credit Agricole CIB, Wells Fargo Securities, Barclays, BBVA, BofA Securities, Credit Suisse, J.P. Morgan, KeyBanc Capital Markets, MUFG, RBC Capital Markets, Scotiabank, Stifel and Truist Securities will act as joint book running managers for the offering.

The offering will be made under an effective shelf registration statement of the Company, the Operating Partnership and MPT Finance Corporation previously filed with the Securities and Exchange Commission (“SEC”). When available, copies of the preliminary prospectus supplement, final prospectus supplement and the prospectus relating to the offering may be obtained by contacting Goldman Sachs & Co. LLC at 200 West Street, New York, NY 10282, telephone: (866) 471-2526 or email: [email protected]; Credit Agricole CIB at 1301 Avenue of the Americas, New York, NY 10019, Attention: Fixed Income Syndicate, email: [email protected]; Wells Fargo Securities at 550 South Tryon Street, 5th Floor, Charlotte, NC 28202, Attention: Leveraged Syndicate, email: [email protected]; or by visiting the SEC’s EDGAR public database at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company or any of its subsidiaries, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospitals with approximately 385 facilities and roughly 42,000 licensed beds in nine countries and across four continents on a pro forma basis. MPT’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “estimate”, “target”, “anticipate”, “believe”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding our strategies, objectives, future expansion and development activities, and expected financial performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) the risk that we may not be able to complete the offering and apply the net proceeds as indicated; (ii) the economic, political and social impact of, and uncertainty relating to, the COVID-19 pandemic, including governmental assistance to hospitals and healthcare providers, including certain of our tenants; (iii) the ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us, especially as a result of the adverse economic impact of the COVID-19 pandemic, and government regulation of hospitals and healthcare providers in connection with same; (iv) risks related to our expectations regarding Adjusted EBITDA, Total Transaction Gross Assets, annual run-rate net income and NFFO per share; (v) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate acquisitions and investments; (vi) the nature and extent of our current and future competition; (vii) macroeconomic conditions, such as a disruption of or lack of access to the capital markets; (viii) our ability to obtain debt financing on attractive terms or at all, which may adversely impact our ability to pursue acquisition and development opportunities and pay down, refinance, restructure or extend our indebtedness as it becomes due; (ix) increases in our borrowing costs as a result of changes in interest rates and other factors, including the transition away from LIBOR after 2021; (x) international, national and local economic, real estate and other market conditions, which may negatively impact, among other things, the financial condition of our tenants, lenders and institutions that hold our cash balances, and may expose us to increased risks of default by these parties; (xi) factors affecting the real estate industry generally or the healthcare real estate industry in particular; (xii) our ability to maintain our status as a REIT for federal and state income tax purposes; (xiii) federal and state healthcare and other regulatory requirements, as well as those in the foreign jurisdictions where we own properties; (xiv) the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain equity or debt financing secured by our properties or on an unsecured basis; (xv) the ability of our tenants and operators to comply with applicable laws, rules and regulations in the operation of the our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract residents and patients; and (xvi) potential environmental contingencies and other liabilities.

The risks described above are not exhaustive and additional factors could adversely affect our business and financial performance, including the risk factors discussed under the section captioned “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, Current Report on Form 8-K filed with the SEC on April 8, 2020 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. Forward-looking statements are inherently uncertain and actual performance or outcomes may vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned to not place undue reliance on forward-looking statements as predictions of future events. We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made.

Drew Babin, CFA

Senior Managing Director – Corporate Communications

Medical Properties Trust, Inc.

(646) 884-9809

[email protected]

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Hospitals Construction & Property Health REIT

MEDIA:

Logo
Logo
Posted on

Robbins LLP Announces It Is Investigating the Officers and Directors of Apollo Global Management, Inc. (APO) on Behalf of Shareholders

Robbins LLP Announces It Is Investigating the Officers and Directors of Apollo Global Management, Inc. (APO) on Behalf of Shareholders

SAN DIEGO & NEW YORK–(BUSINESS WIRE)–
Shareholder rights law firm Robbins LLP announces it investigating whether certain officers and directors of Apollo Global Management, Inc. (NYSE: APO) breached their fiduciary duties to shareholders. Apollo Global Management is a publicly owned investment manager that manages hedge funds, real estate funds and private equity funds for its clients.

Apollo Global Management, Inc. (APO) Shareholders Have Legal Options

Contact us to learn more:

Lauren Levi

(800) 350-6003

[email protected]

Shareholder Information Form

Would you like us to notify you if a class action against Apollo Global Management settles? Would you like to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Lauren Levi

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

[email protected]

(619) 525-3990 or Toll Free (800) 350-6003

www.robbinsllp.com

KEYWORDS: California New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo